Vertex’s Non-Opioid Pain Candidate Hits Marks In Diabetic Peripheral Neuropathy

 
• By Joseph Haas

VX-548, which is set to read out Phase III data in acute pain in early 2024, demonstrated initial efficacy in chronic pain, but analysts say the drug will have to compete mainly on safety and tolerability.

Peripheral neuropathy
Vertex now has Phase II data for VX-528 in chronic pain while getting ready to file in acute pain • Source: Shutterstock

More from Clinical Trials

More from R&D